We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

43 hedge funds and large institutions have $8.97M invested in Clearside Biomedical in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,436% more call options, than puts

Call options by funds: $169K | Put options by funds: $11K

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

0.07% less ownership

Funds ownership: 0.9% → 0.83% (-0.07%)

10% less funds holding

Funds holding: 48 → 43 (-5)

30% less capital invested

Capital invested by funds: $12.8M → $8.97M (-$3.78M)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
6
Closed
14
Calls
$169K
Puts
$11K
Net Calls
+$158K
Net Calls Change
+$28K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$159K
2
BlackRock
BlackRock
New York
+$80.8K
3
State Street
State Street
Massachusetts
+$65.9K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$42.4K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$35.8K

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$286K
2
GGH
GCM Grosvenor Holdings
Illinois
-$252K
3
RA
Rosalind Advisors
Ontario, Canada
-$162K
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$137K
5
Millennium Management
Millennium Management
New York
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$19.2K – – –
Prudential Financial
27
Prudential Financial
New Jersey
$18.4K -$17.5K -1,067 -45%
Mariner
28
Mariner
Kansas
$18K – – –
OC
29
Oppenheimer & Co
New York
$13.6K +$15.7K +956 New
SWA
30
Stratos Wealth Advisors
Ohio
$13.3K – – –
VF
31
Virtu Financial
New York
$13K +$14.8K +900 New
Cambridge Investment Research Advisors
32
Cambridge Investment Research Advisors
Iowa
$10K – – –
Commonwealth Equity Services
33
Commonwealth Equity Services
Massachusetts
$10K – – –
RWM
34
Rockwood Wealth Management
Pennsylvania
$9.95K – – –
JP Morgan Chase
35
JP Morgan Chase
New York
$9.84K – – –
MCC
36
Malaga Cove Capital
California
$9.5K +$11K +667 New
Bank of America
37
Bank of America
North Carolina
$6.11K +$345 +21 +5%
TRCT
38
Tower Research Capital (TRC)
New York
$5.71K +$3.27K +199 +99%
Osaic Holdings
39
Osaic Holdings
Arizona
$1.14K – – –
CIBC Private Wealth Group
40
CIBC Private Wealth Group
Georgia
$1.07K – – –
SS
41
SBI Securities
Japan
$361 +$411 +25 New
Russell Investments Group
42
Russell Investments Group
United Kingdom
$138 – – –
CFD
43
Creative Financial Designs
Indiana
$95 – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$2 – – –
GGH
45
GCM Grosvenor Holdings
Illinois
– -$252K -13,246 Closed
RA
46
Rosalind Advisors
Ontario, Canada
– -$162K -8,481 Closed
Millennium Management
47
Millennium Management
New York
– -$116K -6,068 Closed
JJ
48
Johnson & Johnson
New Jersey
– -$105K -5,499 Closed
Citadel Advisors
49
Citadel Advisors
Florida
– -$78.5K -4,774 Closed
Wolverine Trading
50
Wolverine Trading
Illinois
– -$19.6K -1,124 Closed
1
2
3

CLSD Hedge Fund Activity: Q4 2024 in Review

43 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2024, worth a combined $8.97M — down 30% from $12.8M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CLSD and 9 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 12 added.

The largest buyer was UBS Group, opening a new position worth an estimated $159K. The largest seller was First Manhattan, cutting an estimated $286K.

  • 43 institutional investors held Clearside Biomedical (CLSD) as of Q4 2024, down from 48 in Q3 2024.
  • Funds reported $8.97M of Clearside Biomedical stock for Q4 2024, down 30% quarter-over-quarter.
  • 9 funds opened new Clearside Biomedical positions in Q4 2024 and 14 closed out, a net change of -5 holders.
  • The largest Clearside Biomedical buyer in Q4 2024 was UBS Group, an estimated $159K added.
  • The largest Clearside Biomedical seller in Q4 2024 was First Manhattan, an estimated $286K sold.

Based on aggregated 13F filings for Q4 2024.